JUL 23, 2022 2:08 PM PDT

Anti-inflammatory Compound Shows Promise in Treating Severe COVID-19

WRITTEN BY: Annie Lennon

An anti-inflammatory compound has shown promise in treating systemic inflammation and brain injury in patients with severe COVID-19. The corresponding study was published in Science Translational Medicine.

Hyperinflammation triggered by SARS-CoV-2 is a life-threatening condition and a major cause of disease severity in COVID-19. It involves the excessive activation of multiple immune pathways that can lead to tissue damage, acute respiratory distress syndrome (ARDS), and multi-organ failure. 

In the current study, researchers conducted a Phase 2a clinical study to see whether OP-101, an experimental anti-inflammatory nanotherapeutic, could treat hyper inflammation from COVID-19. To do so, they enrolled 24 patients classified as having 'severe' COVID-19 according to the World Health Organization's seven-point ordinal scale (WHO 7OS), and randomized them to receive either a placebo or different doses of OP-101. 

In the end, the researchers noted that OP-101 reduced inflammatory markers and markers of neurological injury more effectively than placebo treatments. They additionally found that whereas 71% of patients on the placebo required mechanical ventilation or died after 30 or 60 days of treatment, the same was true for just 18% of patients treated with OP-101. 

The researchers further found that 60 days post-treatment, whereas only 3 of 7 patients on placebos survived, the same was true for 14 of 17 patients treated with OP-101. 

"Although this was a small-dose escalation trial, there was clearly a strong signal toward benefit at both acute and chronic time point," said Aaron M. Gusdon, MD, assistant professor in the Vivian L. Smith Department of Neurosurgery with McGovern Medical School at UTHealth Houston, first author of the study.

"The possibility that this therapy could also benefit patients with other diseases that lead to systemic inflammatory responses, including various forms of brain injury, is extremely exciting," he added. 

The researchers note that while their findings are promising, their sample size was small, meaning that a larger study is needed to further evaluate the safety and efficacy of OP-101 in severe COVID-19. 

 

Sources: Science Daily, Science Translational Medicine

 

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
JUL 16, 2022
Drug Discovery & Development
Oxytocin Nasal Sprays Don't Improve Emotion Recognition in Healthy Individuals
JUL 16, 2022
Oxytocin Nasal Sprays Don't Improve Emotion Recognition in Healthy Individuals
Oxytocin nasal sprays do not improve the recognition of emotions such as anger and sadness in healthy men without autism ...
JUL 20, 2022
Neuroscience
What Does the Sleeping Brain Do When It Hears Music?
JUL 20, 2022
What Does the Sleeping Brain Do When It Hears Music?
A study published in Nature Neuroscience highlights brain activity that happens when a sleeping person hears music. A te ...
AUG 16, 2022
Neuroscience
Phone Therapy Shows Promise for Treating Tinnitus
AUG 16, 2022
Phone Therapy Shows Promise for Treating Tinnitus
 A phone-based therapy has shown encouraging results in treating tinnitus in a recent clinical trial. The correspon ...
SEP 13, 2022
Cancer
Emerging Drug Targets in Cancer Immunotherapy
SEP 13, 2022
Emerging Drug Targets in Cancer Immunotherapy
Introduction Cancer is the second leading cause of death globally. According to estimates from the American Cancer Socie ...
SEP 17, 2022
Drug Discovery & Development
Daily Multivitamin May Slow Down Cognitive Decline in Older Adults
SEP 17, 2022
Daily Multivitamin May Slow Down Cognitive Decline in Older Adults
Daily multivitamins may slow down cognitive decline among older adults. The corresponding study was published in Alzheim ...
SEP 22, 2022
Cannabis Sciences
Study of Regulations and Risks Associated with Growing Recreational and Medical Cannabis Market
SEP 22, 2022
Study of Regulations and Risks Associated with Growing Recreational and Medical Cannabis Market
A study published in Environmental Health Perspectives advises state and federal regulators to assess the health and saf ...
Loading Comments...